HELP CENTER

Everything you need to know

Medication management, support, and more

Jump to

Medication questions

Curious about your medication choices or possible side effects? We’ve got you covered with answers to the most common questions.

Workit Flex includes multiple medication options to help members reduce their alcohol use and alcohol cravings, including naltrexone, acamprosate, semaglutide, liraglutide, and tirzepatide.

Semaglutide, tirzepatide, and liraglutide have not been approved by the FDA for treating alcohol use disorder. Your clinician will work with you, your preferences, and your medical history to determine the right medication or medications and create a tailored treatment plan.

Clinicians may also prescribe ondansetron (Zofran® or generic) or thiamine/vitamin B1 if clinically indicated.

Each of these medications works a bit differently to support people in reducing or stopping alcohol use.

  • Naltrexone helps reduce cravings and the “reward” feeling some people get from drinking. It’s one of the most well-studied medications for alcohol use disorder and has been shown in multiple large clinical trials to help people drink less and avoid relapse. It has been used safely for decades in a variety of treatment settings.
  • Acamprosate helps your brain regain balance after cutting back or quitting alcohol, which can reduce withdrawal-related anxiety or restlessness. Acamprosate is backed by a strong body of research showing its effectiveness, particularly when combined with counseling or support.
  • Semaglutide, tirzepatide, and liraglutide may reduce cravings and interest in alcohol. GLP-1 medications were originally developed for diabetes and weight loss, but early research suggests they may also help people drink less. A recent clinical trial of semaglutide among adults with alcohol use disorder found that, compared to individuals who were taking a placebo, individuals taking semaglutide drank less alcohol and had reduced alcohol cravings. Among a subset of participants who also smoked, semaglutide was also associated with reductions in smoking. Other studies of medical records have found that individuals who were prescribed GLP-1s were less likely to have diagnoses of alcohol use disorder, alcohol intoxication, and alcohol-related hospitalizations compared to individuals who were not prescribed GLP-1s. This is an evolving area of research and there are additional clinical trials currently underway.

    Note: The use of semaglutide, tirzepatide, and liraglutide for alcohol use disorder is considered off-label, which means the FDA has not approved them for this purpose. However, prescribers may recommend them based on emerging scientific evidence and clinical judgment.

Possibly. Clinical research shows that medications like naltrexone and acamprosate are most effective while you're actively taking them. Staying on naltrexone or acamprosate long-term is not only safe—it’s recommended by experts for people who find doing so helpful. Studies have found that stopping these medications can increase the risk of relapse—especially within the first few months of treatment—because cravings and alcohol-related triggers may return. That said, not everyone experiences a return of cravings right away. Some people maintain progress after stopping, particularly if they’ve built strong routines, support systems, or therapy tools.

With GLP-1 medications, there isn’t enough evidence yet to know whether long-term treatment is needed when using in an off-label setting for alcohol use disorder. So far, the evidence suggests that, for people who are using GLP-1 medications for weight loss, when people stop taking medications they often regain weight.

The decision to continue or stop should be made together with your healthcare provider, based on your goals, experience, and risk of return to use. If you're considering stopping your medication, we recommend doing it under medical supervision. We can help you monitor for any changes, manage symptoms, and decide together if tapering or switching to a different medication is a better option.

    • Naltrexone: Generally, side effects are mild, and may include nausea, headache, dizziness, tiredness, and rarely liver irritation. Rarely, it can cause mood changes.



    • Acamprosate: Generally, side effects are mild. Diarrhea is the most common side effect, and it usually goes away with time. Some people may also feel anxious or have trouble sleeping. Rarely, it can cause mood changes.



  • GLP-1s: Common side effects include nausea, vomiting, constipation, diarrhea, decreased appetite, and weight loss. These symptoms are most likely to occur when starting or increasing the dose and often improve over time as your body adjusts. Rarely, GLP-1s may cause more serious side effects, including:


    Pancreatitis (inflammation of the pancreas), which can cause severe stomach pain or require hospitalization.


    Gallbladder issues, such as gallstones or inflammation, especially during rapid weight loss.


    Kidney problems, particularly if vomiting or diarrhea leads to dehydration.


    Gastroparesis (slowed stomach emptying), which can lead to ongoing nausea, bloating, or early fullness.


    Possible thyroid concerns: Animal studies linked GLP-1s to thyroid tumors, including medullary thyroid carcinoma. While this hasn’t been shown in humans, people with a personal or family history of this cancer or MEN2 syndrome should not take GLP-1s.


    Vision changes: This can be due to non-arteritic anterior ischemic optic neuropathy, a rare condition that can cause sudden vision loss, or due to worsening of diabetic retinopathy (where rapid improvement in chronically elevated blood sugar can worsen vision). While not common, any sudden changes in vision should be reported immediately.



If you experience serious symptoms—such as severe abdominal pain, vision changes, or signs of dehydration—please contact your provider right away.

 

We'll monitor you closely and help manage any side effects if they arise.

That’s okay—treatment is not one-size-fits-all. If something isn’t working, let your provider know so you can talk about how it’s going and explore other options. You won’t have to continue with a medication that doesn’t help or causes too many side effects.

Possibly. Generally, for weight loss and diabetes, GLP-1 medications are started at a low dose to minimize side effects and gradually increased, as clinically appropriate. A recent clinical trial testing semaglutide for alcohol use disorder used a similar increasing dosing schedule (increasing the dose at 4 weeks and again at 8 weeks). However, not everyone may need the maximum dose or increased dosing. Our licensed clinicians will work with you to find the clinically appropriate dose for you.

Generally, no. None of these medications is at all like Antabuse, which discourages drinking by making you sick if you consume alcohol.

  • Naltrexone: You won’t feel physically sick from drinking, but alcohol may feel less rewarding or pleasurable.
  • Acamprosate: It does not cause sickness when drinking.
  • GLP-1s: These don’t interact directly with alcohol but may lower your interest in drinking. Drinking on GLP-1s can worsen nausea or cause unexpected effects such as slower absorption of alcohol, heartburn, abdominal discomfort, or other effects.

Yes—the use of GLP-1s for cutting back on alcohol or for alcohol use disorder is considered off-label. That means the FDA has approved them for other conditions (like type 2 diabetes, obesity, overweight with at least one weight-related condition, sleep apnea), but not specifically for alcohol use. Prescribers may, and commonly do, prescribe medications for purposes that the FDA has not specifically approved, especially when supported by research and clinical experience.

Early evidence suggests that GLP-1s can reduce alcohol use and related health conditions. A recent clinical trial of semaglutide among adults with alcohol use disorder found that, compared to individuals who were taking a placebo, individuals taking semaglutide drank less alcohol and had reduced alcohol cravings. Among a subset of participants who also smoked, semaglutide was also associated with reductions in smoking. Other studies of medical records have found that individuals who were prescribed GLP-1s were less likely to have diagnoses of alcohol use disorder, alcohol intoxication, and alcohol-related hospitalizations compared to individuals who were not prescribed GLP-1s. This is an evolving area of research and there are additional clinical trials currently underway. Your provider will work with you to understand your preferences and past medical history to create a treatment plan tailored to you and your needs.

Disclaimer: The prescribing of medications that have not been FDA-approved for alcohol use disorder for such purpose is based on the provider’s determination of clinical appropriateness, judgment and available evidence.

Your provider will work with you to choose the most apprpriate medication or medications based on your health history and preferences. They will guide you through the options to make a shared decision, as clinically appropriate.

Support & Billing

Find answers to questions about pricing, payment options, and how to get help if you need support along the way.

Your Workit Flex program will be $99 for the first month, and then $129/month after that. This does not include the cost of medications, which vary in price. Learn more about the estimated medication costs on our Medication page. 

Yes, we understand that things change. You may cancel your membership in Workit Flex at any time, and we will cancel any future charges on your subscription.

Workit Flex is currently only available for self-pay. If you're looking for a program that is covered by insurance, consider our Workit Core program for alcohol.  Click here to learn more about Workit Core. 

Yes, our medical assistant team can help you submit prior authorization requests to your insurance company or pharmacy benefit manager. Please know that we can't guarantee that your insurance company will approve your prior authorization requests, though.

Members may transition from Workit Flex to Workit Core if they’d like. The Workit Core Program is a good fit for people who:

    • Have more complex medical needs (e.g., seeking treatment for co-occurring anxiety or depression, are pregnant, breastfeeding, or planning to become pregnant, or at risk of alcohol withdrawal)

 

    • Desire community connection and behavioral health support

 

  • Want to use a covered insurance plan or pay out-of-pocket

 

If you would like to transition to the Workit Core program, please call our member experience team or send us a message in admin chat.

Yes, clinicians in the Core program are able to prescribe GLP-1s off-label for alcohol use disorder. However, the prescribing of a GLP-1 is subject to clinical discretion and is based on factors such as your medical history and other health conditions. Regardless of whether you are in the Core program or the Flex program, your clinician will work with you to create a tailored treatment program based on your individual needs.